The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Rethinking the war on cancer
Open accessAbstract
Some 40 years ago a metaphor was posed that cancer was such an insidious adversary that a declaration of war on the disease was justified. Although this statement was a useful inspiration for enlistment of resources, despite extraordinary progress in our understanding of disease pathogenesis, in most cases and for most forms of cancer this war has not been won. A second metaphor was about magic bullets--targeted therapies based on knowledge of mechanisms that were envisaged to strike with devastating consequences for the disease. The reality, however, is that targeted therapies are generally not curative or even enduringly effective, because of the adaptive and evasive resistance strategies developed by cancers under attack. In this Series paper, I suggest that, much like in modern warfare, the war on cancer needs to have a battlespace vision.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [28]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Self-citationHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,096
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Economic burden of cancer across the European Union: a population-based cost analysis
Luengo-Fernández, R., Leal, J., Gray, A. M., & Sullivan, R. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70442-x · Cited by 1,055
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R. A., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 972
Global cancer patterns: causes and prevention
Vineis, P., & Wild, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)62224-2 · Cited by 746
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Cancer survival: global surveillance will stimulate health policy and improve equity
Coleman, M. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62225-4 · Cited by 370
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 264
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 249
Cancer stem cells: In the line of fire
Alison, M. R., Lin, W., Lim, S. M. L., & Nicholson, L. J. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.003 · Cited by 228
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 201
Palma, M. D., & Hanahan, D. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.011 · Cited by 188
Self-citationMechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 167
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U. M., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 162
Managing drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 160
Why we're losing the war on cancer (and how to win it).
Leaf, C. (2004) · PubMed · Cited by 150
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 104
Dominant Battlespace Knowledge
Johnson, S. E., & Libicki, M. C. (1996) · Cited by 54
Addressing the Growing International Challenge of Cancer: A Multinational Perspective
VARMUS, H. E., & Kumar, H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005899 · Cited by 45
An appeal to world leaders: stop cancer now
Cavalli, F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60059-8 · Cited by 41
BIM, PUMA, and the Achilles’ Heel of Oncogene Addiction
Roulston, A., Muller, W. J., & Shore, G. C. (2013) · Science Signaling · doi:10.1126/scisignal.2004113 · Cited by 22
The truth in small doses: why we're losing the war on cancer--and how to win it
(2014) · Choice Reviews Online · doi:10.5860/choice.51-5629 · Cited by 18
Winning the War: Science Parkour
Vogelstein, B., & Kinzler, K. W. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004019 · Cited by 13
Cited by
Sorted by citations
Fitzmaurice, C., Allen, C., Barber, R. M., Barregård, L., Bhutta, Z. A., Brenner, H., Dicker, D., Chimed‐Ochir, O., Dandona, R., Dandona, L., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,318
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 785
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S., & Chang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 443
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Block, K. I., Gyllenhaal, C., Lowe, L. J., Amedei, A., Amin, A. R. M. R., Amin, A., Aquilano, K., Arbiser, J. L., Arreola, A., Arzumanyan, A. L., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.007 · Cited by 308
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lü, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 289
Metadata
- Authors
- Hanahan, D.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Hanahan, Douglas
- ORCID
- Hanahan, Douglas
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 383
- Issue
- 9916
- Pages
- 558-563
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2098627399
- Cited by
- 271
- References
- 29
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 10 · 2023: 16 · 2022: 16 · 2021: 26 · 2020: 20 · 2019: 20 · 2018: 25 · 2017: 26 · 2016: 31 · 2015: 35 · 2014: 24
- FWCI
- 36.57
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- war on cancer, cancer, targeted therapy, drug resistance, adaptive resistance, carcinogenesis, cancer treatment strategies
- MeSH terms
- Antineoplastic Agents, Health Planning, Humans, Neoplasms, Anticarcinogenic Agents, Metaphor, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
